

Final Opportunity: Early Bird Conference Tickets and PBAC Comments for Trikafta!

Dear Cystic Fibrosis Community,

Time is of the essence, and we wanted to remind you of two critical deadlines closing as of today, the 31st of January 2024.

Early Bird Tickets for the 2024 Australasian Cystic Fibrosis Conference:

The clock is ticking! This is your last chance to secure Early Bird tickets for our conference in Brisbane. Don't miss out on the special discounted rates. Join us for this exceptional opportunity to connect, learn, and advance our collective efforts in cystic fibrosis care.

*This conference is open to all, with both Medical and Non-Medical sessions available over different days. Take a look at the Program via the Conference Website to learn more.

Secure Your Early Bird Tickets Now

PBAC Comments for Trikafta Extension (Ages 2-5):

Your voice matters! The deadline for submitting comments to the Pharmaceutical Benefits Advisory Committee (PBAC) regarding the extension of Trikafta to children aged 2-5 is closing. This is a crucial opportunity to advocate for expanded access to this life-changing treatment.

* When submitting your comments, search the medicine drop-down for *Elexacaftor with Tezacaftor and with Ivacaftor, and Ivacaftor – Trikafta.*

Submit Your Comments to PBAC Today

Act now to ensure your participation in these pivotal opportunities as we advance outcomes for all Australians living with cystic fibrosis. Your engagement fuels progress and shapes the future for individuals with cystic fibrosis.

Thank you for being an integral part of our community, and we look forward to your continued support. I hope to see you in Brisbane soon!

Warm Regards,

Jo Armstrong CEO Cystic Fibrosis Australia